A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Mullerian Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Ofranergene obadenovec (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors VBL Therapeutics
- 14 Aug 2017 According to a VBL Therapeutics media release,the company provided an update on long-term survival for the phase 2 part from this trial at the BIO International Convention.
- 19 Jun 2017 According to a VBL Therapeutics media release, long-term survival data from this trial will be presented at 2017 BIO International Convention.
- 19 Jun 2017 Long-term survival data from this trial published in a VBL Therapeutics Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History